COMPANY PROFILE

Metagen Therapeutics

Explore full profile

Microbiome-based therapeutics for various intractable diseases.

Tsuruoka-Shi, JapanFounded 2020Biotech & Life Sciences

Valuation $10–25M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Metagen Therapeutics

Metagen Therapeutics (MGTx) is a clinical-stage company operating Japan’s first GMP-compliant manufacturing platform for fecal microbiota transplantation (FMT) therapies. The company combines proprietary paired metagenomic datasets with AI/ML-driven donor-recipient matching to advance precision microbiome medicine across ulcerative colitis, immuno-oncology, and neurodegenerative disease.

Headquartered in Tsuruoka, Japan, MGTx leverages a cross-border regulatory strategy spanning PMDA and FDA pathways, positioning it as a platform bridging Japanese clinical innovation with global market access.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Tsuruoka-Shi, Japan
Employees: 18
Open positions: None listed
Dealroom signal: 62.1/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Core AI, Spinout, Biotech and Pharma, Generative AI, DT and LS, science-based
Technology: Artificial Intelligence
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

7 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Jan 2026	$9.2M	$37M	Canon Marketing Japan MIRAI Fund · Medipal Innovation Fund · Asuka Innovation Fund · Matsukiyo Cocokara	—
SERIES B✓Equity / VC	Sep 2025	$18M	$72M	SMBC Venture Capital · Dentsu Ventures · Mirai Creation fund · JAFCO	—

Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Growth signals

Metagen Therapeutics website traffic

Latest recorded traffic for Metagen Therapeutics is 4.4K monthly website visits, up 46.7% over the last three months. Metagen Therapeutics's team declined 52.6% over the past year.

Latest monthly visits4.4K 3-month web change+46.7% 1-year team growth-52.6%

Monthly website visitsNov 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DBDiffuse BioWe're building push-button software for drug design, driven by breakthroughs in generative AI	San Francisco, United States	Operational	11	$125K	$500K
VIVilyaDeveloping a novel class of drugs that precisely target the biology of disease	Seattle, United States	Operational
MAMenten AILeverages synthetic biology, machine learning and quantum computing to create new proteins not found in nature for diverse applications in the pharmaceutical and chemical industries	San Francisco, United States	Operational
EVEvozyneGenerative AI-powered drug discovery platform and product development	Chicago, United States	Operational
RERevrFormerly Tierra Biosciences. Accelerates bio-discovery using cell-free systems combined with powerful automation tools for data generation	San Leandro, United States	Operational
1S10x ScienceAI-native platform for next-generation protein characterization	San Francisco, United States	Operational
IBiCamuno BiotherapeuticsAI-driven iPSC therapies for cancer and neurological disorders.	Jiuquan, China	Operational
DRDreamFoldDeveloping generative machine learning algorithms to navigate the vast space of proteins to discover medicines	Montreal, Canada	Operational